

THE LANCET

Infectious Diseases

Supplementary appendix 3

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Boum Y, Fai KN, Nicolay B, et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. *Lancet Infect Dis* 2021; published online March 25. [https://doi.org/10.1016/S1473-3099\(21\)00132-8](https://doi.org/10.1016/S1473-3099(21)00132-8).

1 **Appendix**

2 **Table S1: Mean Ct values in PCR-positive participants by clinical presentation and antigen-based RDT**
 3 **results.**

| | SDAg + | SDAg- | p-values |
|--|---------------|--------------|-----------------|
| Symptomatic | 23.65 | 29.30 | <0.001 |
| Asymptomatic | 25.79 | 31.76 | <0.001 |
| Delay from start of symptom to positive PCR <14 days | 22.94 | 29.06 | <0.001 |
| Delay from start of symptom to positive PCR ≥ 14 days | 26.86 | 30.71 | 0.03 |

4

5

6 **Table S2. Performance of each antibody test compared to ELISA (Biomereux, mini VIDAS)**

7

| | Kappa | Sensitivity (95% CI) | Specificity (95% CI) |
|---------------------|--------------|-----------------------------|-----------------------------|
| RunKun | 0.43 | 0.76 (0.58, 0.89) | 0.69 (0.53, 0.82) |
| Innovita | 0.47 | 0.93 (0.88, 0.96) | 0.49 (0.38, 0.60) |
| SD Biosensor | 0.60 | 0.94 (0.80, 0.99) | 0.69 (0.53, 0.82) |
| Wondfo | 0.76 | 0.98 (0.92, 1.00) | 0.75 (0.60, 0.86) |

8

9

10 **Table S3. Cohen's Kappa agreement scores between serological tests.**

| Tests | Innovita (n=928) | Wondfo (n=400) | Biosensor (n=100) | Runkun (n=100) | ELISA (n=200) |
|--------------|-------------------------|-----------------------|--------------------------|-----------------------|----------------------|
| Innovita | | 0.76 | 0.57 | 0.43 | 0.47 |
| Wondfo | | | 0.72 | 0.56 | 0.76 |
| Biosensor | | | | 0.69 | 0.60 |
| Runkun | | | | | 0.43 |

11

12

13

14

15

16

17 **Table S4 : Distribution of participants per type of test**

18

| | Number of participants per test |
|--|--|
| 3 test modalities (PCR, Antibody, Antigen) | 736 |
| PCR | 1140 |
| Antigen SD Biosensor | 958 |
| Antibody SD Biosensor | 87 |
| Antibody Innovita | 952 |
| Antibody Wondfo | 277 |
| Antibody Runkun | 87 |
| Biomerieux Immunoassay | 185 |

| Number of participants between two tests | | | | | | | |
|---|-----|----------------------|-----------------------|-------------------|-----------------|-----------------|-------------------------|
| | PCR | Antigen SD Biosensor | Antibody SD Biosensor | Antibody Innovita | Antibody Wondfo | Antibody Runkun | Biomerieux Immunoassays |
| PCR | | 915 | 85 | 914 | 216 | 85 | 179 |
| Antigen SD Biosensor | | | 77 | 765 | 192 | 76 | 156 |
| Antibody SD Biosensor | | | | 87 | 79 | 85 | 79 |
| Antibody Innovita | | | | | 215 | 86 | 183 |
| Antibody Wondfo | | | | | | 79 | 90 |
| Antibody Runkun | | | | | | | 78 |
| Biomerieux Immunoassays | | | | | | | |

19

20

21

22

23

24

25


26

27

28


29

30



31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47

Figure S1: Flow chart of participants screening, enrolment and testing.



48
 49
 50
 51
 52
 53
 54
 55
 56
 57

Figure S2: Change in SARS-CoV-2 PCR cycle threshold (Ct) values over time and Ct value compared to antigen and antibody test positivity over days since symptom onset. Days since symptom onset are presented on the x-axis, Ct values are presented on the lefthand y-axis, and the rapid diagnostic test (RDT) test positivity is presented on the righthand y-axis with each dot representing an individual positive or negative RDT. Shading represents the 95% confidence interval around the correlation between Ct values and test positivity for each specific RDT. IgM and IgG testing reflect Innovita antibody rapid diagnostic test (RDT) results. Ag reflects antigen RDT, and PCR reflects gold-standard SARS-CoV-2 PCR.